RCS - Cambridge Cognition - Monument Therapeutics Partnership with FNIH

Cambridge Cognition Holdings

19/08/2025 10:10

RNS Number : 9084V

Cambridge Cognition Holdings PLC

19 August 2025

 

August 19, 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia

 

Cambridge UK, August 19, 2025 - Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has today announced a partnership with the Foundation for the National Institutes of Health (FNIH) to evaluate MT1988, a novel treatment in development for cognitive impairment associated with schizophrenia, in a proof of principle clinical trial.

 

Schizophrenia is a serious mental health condition that ranks among the top 15 causes of disability worldwide. Its symptoms include hallucinations, delusions, and cognitive impairments, with many individuals showing early signs during a 'clinical high risk' (CHR) phase, which currently lacks effective treatment options, despite its profound impact on functioning and quality of life.

 

The trial will be conducted as part of the FNIH-managed Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) program, a public-private collaboration involving the National Institutes of Health (NIH), major pharmaceutical companies, and nonprofit organisations with $44 million of investment committed to date. The initiative aims to accelerate the development of more effective treatments for schizophrenia and related mental health conditions.

 

Cambridge Cognition's proprietary digital cognitive assessment technologies supported the early development of MT1988 and were instrumental in establishing the foundational biomarker strategy for Monument. The Company retains a 20% equity stake, valued at £1.8m, and future royalty rights in Monument Therapeutics, following its spin-out in 2021.

 

Rob Baker, Joint Managing Director and Chief Operating Officer, commented:

"Monument's continued progress into patient trials is a significant step in developing precision treatments for brain health. It highlights the value of Cambridge Cognition's digital assessment technology in this field and reinforces our confidence in Monument's strategy, which targets areas of high unmet clinical need and offers strong potential for long-term value through our equity and royalty interests."

 Enquiries

Cambridge Cognition Holdings plc
Rob Baker, Joint Managing Director and Chief Operating Officer
Tel: 012 2381 0700
press@camcog.com
Panmure Liberum Limited (NOMAD and Joint Broker)
Will Goode / Freddy Crossley / Mark Rogers
Rupert Dearden
Tel: 020 7886 2968
(Corporate Finance)
(Corporate Broking)
Dowgate Capital Limited (Joint Broker)
David Poutney / Amber Higgs
Tel: 020 3903 7715
Hudson Sandler (Financial PR and IR)
Dan de Belder / Hattie Dreyfus /Jackson Redley
Tel: 020 7796 4133
cog@hudsonsandler.com

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specialising in digital health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a strong global brand with scalable technology that will support the rising world demand for diagnosing and treating brain health. The Company creates shareholder value through organic sales growth, strategic partnerships, joint ventures, and spinouts.  The Company has identified four market sectors: 

·     Clinical Studies for new pharmaceuticals;

·     Academic Research for scientists to understand CNS disorders;

·     Healthcare to provide physicians with cognitive assessments to allow them to diagnose and treat patients; and,

·     Consumer Health & Wellness to provide individuals access to accurate, reliable, and meaningful data to assess their cognitive health. 

For further information, visit: www.cambridgecognition.com

 

About Monument Therapeutics:

 

Monument Therapeutics is a neuroscience-focused drug development company headquartered in Manchester, UK. It applies a unique novel drug development strategy, leveraging digital assessments of cognition to select patients suitable for treatment with new innovative drugs.

 

For more information, please visit www.monumenttx.com.

 

About the Foundation for the National Institutes of Health:

The Foundation for the National Institutes of Health (FNIH) builds public-private partnerships that connect leading biomedical scientists at the National Institutes of Health (NIH) with their counterparts in life sciences companies, academia, patient organizations, foundations, and regulatory agencies (including the U.S. Food and Drug Administration and European Medicines Agency). Through team science, the FNIH solves complex health challenges and accelerates breakthroughs for patients, regardless of who they are or what health threats they face. The FNIH contributes to the development of new therapies, diagnostics, and potential cures; advances global health; and helps train the next generations of scientists. Established by Congress in 1990 to support the mission of the NIH, the FNIH is a not-for-profit 501(c)(3) charitable organization. For more information about the FNIH, please visit fnih.org. 

 

 

About the Accelerating Medicines Partnership®:

 

Launched in 2014 and managed by the FNIH, the Accelerating Medicines Partnership (AMP) program brings together the National Institutes of Health, U.S. Food and Drug Administration, biomedical and life sciences companies, nonprofits, patient-focused groups, and other organizations to transform the current model for developing new diagnostics and treatments. Using cutting-edge scientific approaches and broad sharing of research data, all AMPs seek to improve understanding of disease pathways, facilitate better selection of targets for drug development, and streamline processes for bringing new treatments to patients. To learn more about AMP, visit fnih.org/AMP.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRASFMSUUEISESA